home / stock / cwbr / cwbr news

CWBR News and Press, CohBar Inc. From 11/16/20

Stock Information
Company Name: CohBar Inc.
Stock Symbol: CWBR
Market: OTC
Website: cohbar.com
Menu
CWBR CWBR Quote CWBR Short CWBR News CWBR Articles CWBR Message Board
Get CWBR Alerts

News, Short Squeeze, Breakout and More Instantly...
CWBR - CohBar, Inc. 2020 Q3 - Results - Earnings Call Presentation

The following slide deck was published by CohBar, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: CohBar, Inc. 2020 Q3 - Results - Earnings Call Presentation

CWBR - CohBar EPS in-line

CohBar (CWBR): Q3 GAAP EPS of -$0.06 in-line.Cash, equivalents and investments of $23.4M.Press Release For further details see: CohBar EPS in-line

CWBR - CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update

MENLO PARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the third quarter ended Septem...

CWBR - CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020

MENLO PARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its third quarter 20...
CWBR - CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis

MENLO PARK, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced it will host a Key Opinion Leader (KOL) webinar on the ...

CWBR - CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, and Chi...

CWBR - CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model

MENLO PARK, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced new preclinical data demonstrating that combination of ...
CWBR - CohBar to Present at the BIO-Europe Conference

MENLO PARK, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will pr...

CWBR - CohBar's CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference

MENLO PARK, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will be...

CWBR - CohBar to Present at the BIO Investor Forum

MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will pr...
Previous 10 Next 10